# Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT04445701** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arch Oncology** · enrollment: 10 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** AO-176
- **DRUG:** AO-176 + Dex
- **DRUG:** AO-176 + Dex + Bort

## Key facts

- **NCT ID:** NCT04445701
- **Lead sponsor:** Arch Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-11-14
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445701, "Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04445701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*